Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 34 % of short-term debt in 2024; threshold 65 %.
-
Late annual account NBB
Fiscal year 2024 was filed 327 days after the legal deadline.
Financials
Financial year 2024
AKSA PHARMA from Brussel, company number BE0651787243, closed financial year 2024 with a result of € -54,052 after tax. For that financial year AKSA PHARMA recorded a gross margin of € 173,998 and equity of € 156,622. Compared with financial year 2023, the result moved from € 154,530 to € -54,052. The company made a loss. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on June 23, 2026.
€ 156,622
▼ 26% vs 2023
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -54,052
▼ still € 154,530 profit in 2023
Profit after tax over the fiscal year.
€ 1,404
▼ 97% vs 2023
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 138,022.
People and assets in 2024
3.6
▲ 0.6 vs 2023
Average over the fiscal year, from the social balance sheet.
€ 185,382
▲ 1% vs 2023
€ 51,500 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2024
€ 99,703
▲ 27% vs 2023
Loans from banks and other lenders, long and short.
€ 172,313
▼ 5% vs 2023
Supplier invoices still open on the last day of the fiscal year.
€ 55,878
▼ 54% vs 2023
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2021 | 2022 | 2023 | 2024 | Change 2023 → 2024 | |
|---|---|---|---|---|---|
| Gross margin | € 250,159 | € 375,824 | € 438,339 | € 173,998 | ▼ 60% |
| Profit after taxes | € 74,271 | € 168,430 | € 154,530 | € -54,052 | ▼ € 208,582 |
| Equity | € -112,286 | € 56,144 | € 210,674 | € 156,622 | ▼ 26% |
| Total debts | € 689,696 | € 589,133 | € 417,135 | € 367,641 | ▼ 12% |
| Cash | € 49,993 | € 119,968 | € 49,966 | € 1,404 | ▼ 97% |
| Retained profit | € -130,886 | € 37,544 | € 192,074 | € 138,022 | ▼ 28% |
| Bank debt | € 299,418 | € 187,421 | € 78,589 | € 99,703 | ▲ 27% |
| Balance sheet total | € 577,410 | € 645,277 | € 627,809 | € 524,262 | ▼ 16% |
| Employees (FTE) | - | 3 | 3 | 3.6 | ▲ 0.6 |
Key figures of AKSA PHARMA, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.
What happened to AKSA PHARMA?
What happened at AKSA PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2024: loss of € 54,052 (▼ € 208,582 vs 2023). filed late Source: NBB ↗
- New establishment in Sint-Lambrechts-Woluwe. KBO
- Start of the company according to the CBE. KBO
In short
From € 74,271 profit in 2021 to € 54,052 loss in 2024.
Paid € 80,465 in corporate taxes since 2021.
Best year ever: 2022, with € 168,430 profit.
On average € 48,300 of value added per employee in 2024.
A new publication or filing at AKSA PHARMA? We notify you, reason included.
Follow AKSA PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind AKSA PHARMA is RICHARD BONTEMPS.
Directors
According to the 2024 annual accounts
RICHARD BONTEMPS
Administrator-manager
Establishments
Establishment units
Physical locations of this company
Araucarialaan 79
1020 Brussel
Woluwedal 70 box 14
1200 Sint-Lambrechts-Woluwe
Active since 14 May 2016
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 3 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0651.787.243
- VAT number
- BE 0651.787.243
- Registered office
- Araucarialaan 79, 1020 Brussel
- Names & denominations
- AKSA PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 11 April 2016
- Peppol
- Active · Active since 15 Dec 2025
- Activities · NACE
Detailhandel in farmaceutische producten